Baebies Announces Assays for FINDER Launch Panel: G6PD, Total Serum

Bilirubin, Albumin and Direct Bilirubin

Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced
the first assays on the FINDER launch panel, currently under development. The panel includes tests
for total serum bilirubin, albumin, direct bilirubin, and glucose-6-phosphate dehydrogenase
(G6PD) on a single cartridge, making it the first comprehensive, rapid and near-patient testing
solution for hyperbilirubinemia.

Durham, NC, July 31, 2017 --(PR.com)-- Experience a hands-on demonstration of FINDERTM at Booth
855 during AACC 2017.

Baebies, Inc., a company focused on advancing newborn screening and pediatric testing, announced the
first assays on the FINDER launch panel, currently under development. The panel includes tests for total
serum bilirubin, albumin, direct bilirubin, and glucose-6-phosphate dehydrogenase (G6PD) on a single
cartridge, making it the first comprehensive, rapid and near-patient testing solution for
hyperbilirubinemia. A robust pipeline of future panels for other disorders using the same cartridge on
FINDER is also in development.

Hyperbilirubinemia is a condition in which bilirubin levels in the blood are elevated and the newborn
becomes jaundiced. When unmonitored or untreated, neonatal jaundice can lead to severe neurotoxicity,
including kernicterus and other associated morbidities.

There is currently a gap in point of care testing devices for G6PD, a deficiency that leads to
hyperbilirubinemia and approximately 21% of kernicterus cases. The FINDER launch panel will address
a critical need for G6PD testing and brings together the most common analytes used to assess
hyperbilirubinemia. Each test on the FINDER launch panel contributes to a more complete understanding
of why jaundice develops in a newborn. Rapid access to these measurements may allow clinicians to treat
severe neonatal hyperbilirubinemia faster and more effectively, thereby preventing irreversible
neurological damage.

Our neonates have very limited volume of blood available for the many tests and technologies required
for current hyperbilirubinemia standard of care. Identifying newborns at-risk for hyperbilirubinemia using
a single drop of blood on FINDER not only reduces the amount of pain a neonate must endure, but also
reduces the time to provide physicians with important information that will direct care, says Dr. Michael
Cotten, Director of Neonatology Clinical Research at Duke University School of Medicine.

FINDER is the only platform specifically designed to address the unique needs of neonatal testing.
FINDER substantially decreases both sample size and testing time, enables testing in the nursery or
anywhere in the hospital, and delivers comprehensive test panels - even across multiple test types - to
solve acute problems in neonatology. Simple operations and test flexibility enable FINDER to provide
results in minutes. A hands-on demonstration of FINDER will be held at Booth 855 during the AACC
Annual Scientific Meeting & Clinical Lab Expo in San Diego, California from August 1-3, 2017.

Page 1/3
PR.com Press Release Distribution Terms of Use
About Baebies, Inc.
At Baebies our sole focus is to advance newborn screening and other pediatric testing worldwide. Baebies
is guided by the vision that everyone deserves a healthy start. Baebies delivers innovative products and
services to make life better for millions of babies. By bringing new technologies and new tests to the
healthcare community, Baebies is providing hope to parents and the chance at a better life to newborns.
FINDER is not available at this time for sale or use in any territory. For more information visit
www.baebies.com.

Contact:
Jessica Kettler
Jkettler@baebies.com
919-328-8332

Page 2/3
PR.com Press Release Distribution Terms of Use
Contact Information:
Baebies
Jessica Kettler
919-328-8332
Contact via Email
www.baebies.com

Online Version of Press Release:

You can read the online version of this press release at: http://www.pr.com/press-release/724944

Page 3/3
PR.com Press Release Distribution Terms of Use